ESC 365 - Outlining the clinical evidence landscape for FXI(a) inhibition: - stroke and bleeding prevention for patients with AF at risk of stroke - secondary stroke prevention in acute non-cardioembolic ischemic stroke or high-risk TIA

Open Access

Outlining the clinical evidence landscape for FXI(a) inhibition: - stroke and bleeding prevention for patients with AF at risk of stroke - secondary stroke prevention in acute non-cardioembolic ischemic stroke or high-risk TIA

Session: How can targeting FXI(a) advance antithrombotic therapy for stroke prevention?

Topic: Stroke in Atrial Fibrillation

Speaker: Professor J. De Groot (Amsterdam, NL) Professor M. Sharma (Hamilton, CA)

Sponsored by Bayer

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speakers

Professor Joris R De Groot

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

16 presentations

3 followers

Professor Mukul Sharma

Population Health Research Institute, Hamilton (Canada)

4 presentations

0 follower

5 more presentations in this session

Welcome and introduction

Speaker: Professor M. Sharma (Hamilton, CA)

Epidemiology of stroke and disease burden

Speaker: Professor M. Blomstrom-Lundqvist (Orebro, SE)

Uncovering the unmet need for patients: - with atrial fibrillation at risk of stroke - acute non-cardioembolic ischemic stroke or high-risk TIA

Speaker: Professor M. Blomstrom-Lundqvist (Orebro, SE) Professor M. Sharma (Hamilton, CA)

Evolution of FXI(a) as a target for antithrombotic therapy

Speaker: Doctor J. Weitz (Hamilton, CA)

Q&A and closing remarks

Access the full session

How can targeting FXI(a) advance antithrombotic therapy for stroke prevention?

Speakers: Professor J. De Groot, Professor M. Sharma, Professor M. Sharma, Professor M. Blomstrom-Lundqvist, Professor M. Blomstrom-Lundqvist...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

novartis

Explore sponsored resources